Promising results from the first-in-human phase I/II clinical trial of ensartinib (NCT01625234) demonstrated that it is effective and generally well-tolerated in patients with ALK-positive NSCLC [5]. This evidence concerns the gene ALK and non-small cell lung carcinoma.